Novel Amyloid Drug Improves Mid-Term Outcomes in ATTR Cardiomyopathy

(MedPage Today) -- AMSTERDAM -- Novel anti-amyloid agent acoramidis improved a composite of outcome endpoints in the pivotal ATTRibute-CM trial for transthyretin mediated amyloidosis (ATTR) cardiomyopathy, with suggestion of clinical normalization...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news